Vaxart, Inc. (VXRT)

0.5724 -0.1775 (-23.67%) 收市：04:00PM EDT

Vaxart, Inc.

170 Harbor Way
Suite 300
South San Francisco, CA 94080
United States
650 550 3500
https://vaxart.com

版塊: Healthcare
行業: Biotechnology
全職員工: 109

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Sean N. Tucker Ph.D.	Senior VP & Chief Scientific Officer	561.1k	無	1968
Dr. James F. Cummings M.D.	Chief Medical Officer	594.5k	無	1966
Mr. Steven Lo	President, CEO & Director	無	無	1967
Mr. Phillip Eric Lee	CFO, Principal Financial Officer & Principal Accounting Officer	無	無	1988
Dr. Raymond D. Stapleton Jr., Ph.D.	Chief Technology Officer	無	無	1971
Mr. Edward B. Berg	Senior VP & General Counsel	無	無	1964
Ms. Shaily Jaini Garg	Senior Vice President of Clinical Development & Project Management	無	無	無
Dr. Rajesh Kapoor Ph.D.	Senior Vice President of Quality	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.

公司管治

截至 2024年6月1日 止，Vaxart, Inc. 的 ISS 管治質素評分為 9。 Pillar 分數正在審核中：9；董事會：7；股東權利：6；現金賠償：9。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。